Beximco And Mylan Strike Biosimilars Deal
First Launch In Bangladesh Will Be Trastuzumab Biosimilar Ogivri
Bangladesh’s Beximco will market Mylan’s biosimilars in its domestic market, under a deal that has just been struck between the two companies. The Ogivri trastuzumab biosimilar, co-developed by Mylan and Biocon, will be the first product launched as part of the collaboration.
